US › Healthcare

Surrozen Inc (SRZN)

US · Healthcare · Biotechnology

$22.00+1.01%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$5.0M
Revenue YoY
+408.6%
Net profit
$-127.5M
Profit YoY
-372.8%
EPS
$-4.63
EPS estimate
$-0.72
Net margin
-2,550.1%

EPS came in at -4.63 against a street estimate of -0.72 — a miss of 543.1%.

Key statistics

Market cap
$257.9M
Forward P/E
0.0
P/B
2.50
Book value
$-24.21
EPS (TTM)
$-36.59
52-week high
$35.00
52-week low
$9.03
50-day MA
$23.35
200-day MA
$22.81
Beta
0.51

Analyst view

Analysts rate Surrozen Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $42.50.

Shareholding

Insiders
3.18%
Institutions
100.10%

Largest institutional holders

FundStake
TCG Crossover Management, LLC12.69%
Kalehua Capital Management LLC6.64%
Boxer Capital Management, LLC6.60%
Millennium Management LLC6.30%
StemPoint Capital LP6.22%
VR Adviser, LLC5.45%
Spruce Street Capital LP3.72%
BRAIDWELL LP3.41%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Surrozen Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.